NRx Pharmaceuticals out of Radnor has once again filed an application with the Food and Drug Administration for emergency use of its experimental COVID-19 drug candidate, Zyesami, writes John George for Philadelphia Business Journal.

The drug would be used on critical patients with COVID-19 who are at immediate risk of death from respiratory failure and who have already received an approved therapy, including Remdesivir.

This is the second time it has sought emergency approval. The application was rejected last year by the FDA.

“As the omicron surge continues to push our hospitals far past capacity, and with more than 1,200 Americans dying every day, we continue to believe Zyesami can provide an option to the sickest of Covid patients who have no other options and significantly increase their chances at recovering,” said Dr. Jonathan Javitt, chairman and CEO of NRx.

NRx Pharmaceuticals’ stock opened up 6% on Jan. 5 at $5 per share.

The company’s stock price has fluctuated during the pandemic.  It’s traded as high as $64.20 per share and as low as $4.07.

NRx did receive an emergency use authorization in July for Zyesami in the nation of Georgia.

Read more at Philadelphia Business Journal about NRx latest emergency use request for its COVID-19 therapy.

Here’s more information on the new filing with the FDA and NRx stock performance as of Dec. 29, 2021.